




which include examples 21 and 23 (table on page 17):




Example 21





Example 23

$IC_{50}$'s are given in CN 114874186 for examples 21 and 23 as 29.22 nM and 11.26 nM respectively.

## SUMMARY

In one aspect, the present disclosure provides a compound of formula (**I**)




(**I**)

wherein

**A** is **A1a** which is a 5- or 6-membered mono-heteroaryl ring containing one or two heteroatom members selected from the group consisting of nitrogen, oxygen and sulphur; wherein at least one of the heteroatom members is nitrogen;

or **A** is **A1b** which is a 9- or 10-membered fused bicyclic-heteroaryl ring containing one to four heteroatom members selected from the group consisting of nitrogen, oxygen and sulphur, wherein at least two of the heteroatom members is nitrogen;

$\mathbf{R^1}$ is selected from the group **R1e**, consisting of F;





$\mathbf{R^2}$ is selected from the group **R2a**, consisting of H, halo, hydroxy, $C_{1-6}$-alkyl, $C_{2-6}$-alkynyl, $C_{3-6}$-cycloalkyl, 1-methyl-$C_{3-6}$-cycloalkyl, $F_{1-9}$-fluoro-$C_{1-6}$-alkyl, HO-$C_{1-6}$-alkyl, $C_{1-6}$-alkyloxy, $C_{1-4}$-alkyl-O-$H_2CH_2C$-O-, $C_{3-6}$-cycloalkyloxy, $C_{3-6}$-cycloalkyl-$H_2C$-O-, $F_{1-9}$-fluoro-$C_{1-4}$-alkyloxy, $C_{1-6}$-alkyl-O-C(O)-, $H_2N$-C(O)- and $C_{1-6}$-alkyl-NH-C(O)-;

$\mathbf{R^3}$ is selected from the group **R3a**, consisting of H, $C_{1-4}$-alkyl, $F_{1-9}$-fluoro-$C_{1-4}$-alkyl and halo;







$\mathbf{R^4}$ is selected from the group **R4a**, consisting of halo, $C_{1-4}$-alkyl, $C_{3-6}$-cycloalkyl, -CN, $C_{1-6}$-alkyloxy, $C_{1-6}$-alkyl-O-C(O)-, $F_{1-9}$-fluoro-$C_{1-4}$-alkyl, $F_{1-9}$-fluoro-$C_{1-4}$-alkyloxy, $C_{3-6}$-cycloalkyloxy, $C_{3-6}$-cycloalkyl-$H_2C$-O-, benzyloxy, (HO)$(H_3C)_2$-C- and HO-C$(H_3C)_2H_2CH_2C$-O-;

or a salt thereof, particularly a pharmaceutically acceptable salt thereof.

In another aspect, the present disclosure provides a compound selected from the group consisting of


,

,

,

,

5


,

,

,

,

and

;

or a salt thereof.

In another aspect, the present disclosure provides a pharmaceutically acceptable salt of a compound as described herein.

In another aspect, the present disclosure provides a pharmaceutical composition comprising one or more compounds as described herein, or pharmaceutically acceptable salts thereof, optionally together with one or more inert carriers and/or diluents.

In another aspect, the present disclosure provides a pharmaceutical composition comprising one or more compounds as described herein, or pharmaceutically acceptable salts thereof, and one or more additional therapeutic agents, optionally together with one or more inert carriers and/or diluents.

In another aspect, the present disclosure provides the compound as described herein or a pharmaceutically acceptable salt thereof for use as a medicament.

In another aspect, the present disclosure provides a compound as described herein or a pharmaceutically acceptable salt thereof for use in the treatment of diseases, such as cancer or fibrotic diseases, and conditions associated with these diseases.


In another aspect, the present disclosure provides use of a compound as described herein or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of diseases, such as cancer or fibrotic diseases, and conditions associated with these diseases.

In another aspect, the present disclosure provides a compound as described herein or a pharmaceutically acceptable salt thereof for use in the treatment of cancer, fibrotic diseases, neurodegenerative diseases, atherosclerosis, infectious diseases, or chronic kidney diseases.

In another aspect, the present disclosure provides use of a compound as described herein or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cancer, fibrotic diseases, neurodegenerative diseases, atherosclerosis, infectious diseases, or chronic kidney diseases.

## DETAILED DESCRIPTION OF THE INVENTION

The present invention discloses novel phenylpiperidine derivatives of formula (**I**)




(**I**)